INCB-123667 is under clinical development by Incyte and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
"This is the first time researchers have been able to indirectly target ovarian cancer cells in peritoneal fluid by inducing an immune reaction, in preclinical models," said Zhang. "We look ...